case study final
.docx
keyboard_arrow_up
School
Northeastern University *
*We aren’t endorsed by this school
Course
6463
Subject
Medicine
Date
Dec 6, 2023
Type
docx
Pages
9
Uploaded by DeaconTeam12693
BKK: COMMERCIALIZING A NEW DRUG
A CASE STUDY
1) In 2-3 paragraphs please present a situational description of the case that addresses:
What is BKK? Where is its intended geographic market? What is its intended indication for
use from a clinical perspective?
What are the alternative paths to market from a regulatory perspective? (A description
here is fine, as opposed to an analysis)
Who are the stakeholders involved in the commercialization process for BKK?
BKK is a nonopioid anaesthetic medication formulation developed by Dr. Brad Worthington,
a medical specialist with vast experience in the field. This formulation combines three FDA-
approved medications: bupivacaine, ketorolac, and ketamine to generate a locally infiltrated
pain relief for use in surgical operations. The novel combination of these medications in BKK
provides a number of clinical benefits, including the prevention of nausea and inflammation,
both of which are typical causes of surgical patient pain. Importantly, BKK is extremely
successful at reducing, and in many cases eliminating the need for opiate pain medications
during and after surgery. From a clinical perspective, BKK is intended to be used in surgical
procedures to provide pain relief at the surgical site. Its unique formulation and properties
make it particularly well-suited for a range of surgical specialties, including orthopaedic,
hernia, plastic, breast, gall bladder, and other surgeries. The clinical goal of BKK is to enhance
postoperative pain management, minimize opioid use, reduce patient discomfort, and
accelerate post-surgery recovery. BKK's intended clinical use aligns with Dr. Worthington's
commitment to reducing opioid exposure and dependency in surgical patients.
From a regulatory perspective, there are three alternative paths to market for BKK:
New Drug Application (NDA):
This path involves seeking institutional investment to fund the
NDA process with the FDA. It offers additional patent protection and the support of
institutional partners for marketing, production, and distribution. However, it carries risks
such as potential litigation costs, loss of control, and competition from other pharmaceutical
companies. The NDA process requires significant time and financial resources.
Compounding Pharmacy Partnership:
BKK can be produced and marketed as a combination
drug in partnership with compounding pharmacies. This option involves less regulatory
approval but is subject to federal restrictions on marketing and promotion of compounded
drugs. It is associated with moderate growth potential and fewer up-front costs.
Convenience Kit:
Developing and marketing a convenience kit containing the separate
components of BKK offers longer shelf life and a more traditional pharmaceutical sales
model. It allows for easier distribution and sales promotion. This option involves higher per-
dose costs but no up-front costs.
The stakeholders involved in the commercialization process for BKK include Dr. Brad
Worthington, the inventor, and medical professional; Thurman Ballard, an independent
consultant in the healthcare industry; potential investors, such as private equity firms;
compounding pharmacies, as potential manufacturing partners; healthcare institutions and
systems, such as Medical Leaders in Healthcare (MLH) and AngelHealth; surgeons and
medical professionals who would administer BKK; and patients, who would benefit from
improved postoperative pain management and reduced opioid exposure. Each stakeholder
plays a crucial role in determining the path to market and the eventual success of BKK in
addressing the opioid crisis and improving patient care in surgical settings.
2) What is Worthington struggling with? What are the challenges he faces in bringing BKK
to market?
Dr. Brad Worthington is encountering a number of problems and difficulties in bringing BKK,
his patented formulation of nonopioid anaesthetic medicines, to market:
Financial constraints:
are one of the most significant issues Worthington faces. He put
$150,000 of his retirement assets into the creation and patenting of BKK. He also anticipates
recurring fees, such as the upkeep of his patent. These financial constraints limit his ability to
pursue certain routes to market, particularly the costly New Drug Application (NDA) process,
which could necessitate millions of dollars in upfront expenditure. [CITATION Gol \l 16393 ]
Competitive Landscape:
The pharmaceutical industry is highly competitive, and several
major pharmaceutical companies are developing their own long-acting nonopioid analgesics.
These potential competitors could pose significant challenges, including patent challenges
and potential litigation, which might inhibit BKK's commercialization and overall success.
Regulatory Obstacles:
Each prospective market entry strategy for BKK entails navigating
complex regulatory processes. An NDA requires FDA clearance and significant money.
Because of federal limits on selling compounded pharmaceuticals, collaborating with
compounding pharmacies entails regulatory constraints. Creating a convenience kit also
necessitates regulatory considerations, such as clinical and packaging testing.
Risk Assessment:
Worthington and Thurman Ballard must carefully assess the risks
associated with each commercialization option. These risks include potential litigation, loss
of control, competition, and the likelihood of success. Each path has its own set of risks, and
the wrong decision could have significant consequences for BKK's future.
Limited Resources:
Because Worthington and Ballard have limited resources, they must
carefully spend their existing finances in order to make the best strategic judgments. They
must assess the ROI, the time required for commercialization, and the possible influence on
treating the opioid issue.
Stakeholder Management:
Various stakeholders are involved in the commercialization
process, including potential investors, compounding pharmacies, healthcare institutions,
surgeons, and patients. The hurdles of the commercialization path include managing these
connections, aligning interests, and gaining crucial collaborations.
Worthington's main challenges are financial constraints, regulatory difficulties,
competitiveness, risk assessment, resource allocation, and stakeholder management. To
effectively bring BKK to market and meet Worthington's vision of lowering opioid exposure
and improving postoperative pain management, these issues must be carefully considered,
and smart decisions must be made.
3) How does the opioid public health crisis relate to the aforementioned challenges,
regulatory or otherwise?
The opioid public health epidemic is inextricably linked to Dr. Brad Worthington's obstacles
and regulatory considerations in bringing BKK to market. Worthington's commitment to
tackle the opioid issue is a motivating motivation for the creation of BKK and has a
substantial impact on the decisions and challenges he faces.
In response to the opioid crisis, the regulatory landscape has evolved, with regulatory bodies
being more watchful and cautious about opioid-related products. This increased scrutiny
influences Worthington's regulatory path, since BKK must meet high standards and prove its
effectiveness in reducing opiate usage. For example, in a study published about minimizing
post operative opioid usage after a Hip Arthroscopy, it said – “In patients undergoing a hip
arthroscopy, performing a pre-operative PENG block and intra-operative BKK pericapsular
injection will result in decreased postoperative pain, PACU time, and inpatient and
outpatient opioids compared to general anaesthesia only and general anaesthesia with
intracapsular Marcaine.” [ CITATION Wid23 \l 16393 ]
The opioid crisis has highlighted the critical need for nonopioid pain management solutions,
especially in surgical settings. The opioid crisis has generated a clinical necessity for solutions
such as BKK that can reduce opioid use before and after surgery, coinciding with the broader
healthcare objective of addressing the opioid problem. The opioid problem has serious
financial consequences for the healthcare system, including the expenses of opioid-related
treatment and healthcare consumption. BKK's ability to reduce opioid use has the potential
to directly impact healthcare costs, making it an appealing alternative for healthcare
providers and hospitals. The opioid crisis has resulted in a greater understanding among
patients and healthcare providers about the hazards and repercussions of opioid usage.
Patients are becoming increasingly concerned about opioid-related adverse effects and
addiction, while doctors are actively looking for nonopioid alternatives.[ CITATION Sto19 \l
16393 ] This increased awareness strengthens BKK's value offer.
In this atmosphere, healthcare stakeholders are more ready to work on opioid-reduction
measures. Nonopioid alternatives are being investigated and supported by surgeons,
hospitals, and pharmaceutical corporations. Primary prevention of opioid addiction is
possible when non-opioid analgesic drugs are used. Employing alternative analgesic drugs in
the peri-operative period that have a lower addiction potential and less respiratory
depression has therefore become a matter of great national importance. [ CITATION Boh20 \l
16393 ] Worthington may use this collaborative environment to seek partnerships and
sponsorships for BKK. The opioid epidemic not only inspires the development of nonopioid
alternatives such as BKK, but it also shapes the regulatory landscape, clinical need, financial
concerns, stakeholder engagement, and market dynamics. While it brings hurdles, it also
gives Worthington and BKK with a compelling potential to have a real impact on opioid
usage in surgical settings and solve a vital public health issue.
4) How would you evaluate the risks and benefits associated with each alternative
pathway for bringing BKK to market?
Evaluating the risks and benefits of each alternative pathway for bringing BKK to market
requires a nuanced assessment that takes into account various factors specific to the
situation:
NDA Pathway
(Option 1):
Benefits:
Pursuing a New Drug Application (NDA) offers enhanced patent protection and
institutional support for marketing, production, and distribution. It aligns with the rigorous
FDA regulatory standards, establishing BKK as a novel drug.
Risks:
The NDA process is costly, time-consuming, and carries a risk of failure, with
significant upfront and ongoing financial investments required. Litigation challenges from
larger pharmaceutical companies are also a concern. Moreover, the lengthy approval
timeline delays market entry.
Evaluation:
This pathway presents potential long-term benefits in terms of patent protection
and market positioning, but it involves substantial financial risks and uncertainties due to the
competitive landscape and lengthy approval process.
Compounding Pharmacy Partnership
(Option 2):
Benefits:
Partnering with a compounding pharmacy offers a faster route to market with
lower upfront costs. BKK can leverage existing relationships with medical professionals and
organizations, providing a moderate growth opportunity.
Risks:
Regulatory limitations on marketing compounded drugs may hinder widespread
adoption. Moreover, the level of control over the product may be reduced, and the revenue
growth potential might plateau over time.
Evaluation:
This option is less financially risky and offers a quicker entry to market but may
have limitations in terms of scalability and long-term growth.
Convenience Kit
(Option 3):
Benefits:
A convenience kit provides an attractive packaging solution, enabling traditional
pharmaceutical sales and leveraging sales representatives. It has potential for a larger
market due to a longer shelf life and ease of use.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help